[{"address1": "4 Kingsbury Avenue", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "617 607 0800", "fax": "617 607 0530", "website": "https://www.enanta.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 131, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jay R. Luly Ph.D.", "age": 68, "title": "President, CEO & Director", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 1231428, "exercisedValue": 0, "unexercisedValue": 67815}, {"maxAge": 1, "name": "Mr. Paul J. Mellett Jr.", "age": 69, "title": "Chief Financial & Administrative Officer", "yearBorn": 1955, "fiscalYear": 2024, "totalPay": 671700, "exercisedValue": 0, "unexercisedValue": 21320}, {"maxAge": 1, "name": "Dr. Yat Sun Or Ph.D.", "age": 72, "title": "Chief Scientific Officer", "yearBorn": 1952, "fiscalYear": 2024, "totalPay": 740108, "exercisedValue": 0, "unexercisedValue": 22091}, {"maxAge": 1, "name": "Mr. Matthew P. Kowalsky J.D.", "age": 51, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 575652, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Scott T. Rottinghaus M.D.", "age": 50, "title": "Chief Medical Office", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 776138, "exercisedValue": 43483, "unexercisedValue": 14728}, {"maxAge": 1, "name": "Ms. Jennifer  Viera", "title": "Executive Director of Investor Relations & Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nathaniel S. Gardiner J.D.", "age": 70, "title": "Consultant", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 672675, "exercisedValue": 49136, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tara Lynn Kieffer Ph.D.", "age": 46, "title": "Chief Product Strategy Officer", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 496852, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brendan  Luu", "age": 49, "title": "Chief Business Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 622856, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 3, "compensationRisk": 6, "shareHolderRightsRisk": 8, "overallRisk": 6, "governanceEpochDate": 1740787200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 7.18, "open": 7.14, "dayLow": 6.915, "dayHigh": 7.3, "regularMarketPreviousClose": 7.18, "regularMarketOpen": 7.14, "regularMarketDayLow": 6.915, "regularMarketDayHigh": 7.3, "payoutRatio": 0.0, "beta": 0.481, "forwardPE": -1.4979252, "volume": 159529, "regularMarketVolume": 159529, "averageVolume": 589066, "averageVolume10days": 383480, "averageDailyVolume10Day": 383480, "bid": 7.16, "ask": 7.24, "bidSize": 1, "askSize": 1, "marketCap": 154020640, "fiftyTwoWeekLow": 4.71, "fiftyTwoWeekHigh": 17.8, "priceToSalesTrailing12Months": 2.3129349, "fiftyDayAverage": 6.0878, "twoHundredDayAverage": 10.363025, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 158619968, "profitMargins": -1.5757099, "floatShares": 14292378, "sharesOutstanding": 21332500, "sharesShort": 3572627, "sharesShortPriorMonth": 3232743, "sharesShortPreviousMonthDate": 1736899200, "dateShortInterest": 1739491200, "sharesPercentSharesOut": 0.1675, "heldPercentInsiders": 0.06579, "heldPercentInstitutions": 0.96103996, "shortRatio": 7.17, "shortPercentOfFloat": 0.17790002, "impliedSharesOutstanding": 21332500, "bookValue": 5.241, "priceToBook": 1.3775996, "lastFiscalYearEnd": 1727654400, "nextFiscalYearEnd": 1759190400, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -104928000, "trailingEps": -4.95, "forwardEps": -4.82, "enterpriseToRevenue": 2.382, "enterpriseToEbitda": -1.472, "52WeekChange": -0.5238727, "SandP52WeekChange": 0.121255875, "quoteType": "EQUITY", "currentPrice": 7.22, "targetHighPrice": 21.0, "targetLowPrice": 5.0, "targetMeanPrice": 15.14286, "targetMedianPrice": 18.0, "recommendationKey": "none", "numberOfAnalystOpinions": 7, "totalCash": 216691008, "totalCashPerShare": 10.158, "ebitda": -107765000, "totalDebt": 221290000, "quickRatio": 5.237, "currentRatio": 5.467, "totalRevenue": 66591000, "debtToEquity": 197.905, "revenuePerShare": 3.142, "returnOnAssets": -0.17749001, "returnOnEquity": -0.691, "grossProfits": 66591000, "freeCashflow": -77771624, "operatingCashflow": -70577000, "revenueGrowth": -0.058, "grossMargins": 1.0, "ebitdaMargins": -1.61831, "operatingMargins": -1.38823, "financialCurrency": "USD", "symbol": "ENTA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Enanta Pharmaceuticals, Inc.", "messageBoardId": "finmb_345286", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "longName": "Enanta Pharmaceuticals, Inc.", "regularMarketChangePercent": 0.55710256, "regularMarketPrice": 7.22, "corporateActions": [], "postMarketTime": 1741382400, "regularMarketTime": 1741381202, "exchange": "NMS", "earningsTimestamp": 1739221260, "earningsTimestampStart": 1746442740, "earningsTimestampEnd": 1746792000, "earningsCallTimestampStart": 1715027400, "earningsCallTimestampEnd": 1715027400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -4.95, "epsForward": -4.82, "epsCurrentYear": -4.96, "priceEpsCurrentYear": -1.4556451, "fiftyDayAverageChange": 1.1321998, "fiftyDayAverageChangePercent": 0.18597847, "twoHundredDayAverageChange": -3.143025, "twoHundredDayAverageChangePercent": -0.30329224, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1363872600000, "postMarketChangePercent": 0.0, "postMarketPrice": 7.22, "postMarketChange": 0.0, "regularMarketChange": 0.03999996, "regularMarketDayRange": "6.915 - 7.3", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 589066, "fiftyTwoWeekLowChange": 2.5099998, "fiftyTwoWeekLowChangePercent": 0.5329086, "fiftyTwoWeekRange": "4.71 - 17.8", "fiftyTwoWeekHighChange": -10.58, "fiftyTwoWeekHighChangePercent": -0.59438205, "fiftyTwoWeekChangePercent": -52.387268, "marketState": "CLOSED", "displayName": "Enanta Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-03-08"}]